Go to Admin » Appearance » Widgets » and move Gabfire Widget: Social into that MastheadOverlay zone
Reality TV star Kim Kardashian is no stranger to criticism, having spent the better part of the last decade in the public eye. But she’s probably never faced negative publicity like this before: The Food and Drug Administration says Kardashian’s social media posts violate federal drug-promotion rules.
Kardashian recently began promoting a prescription pill to treat morning sickness through her social media accounts. Such endorsement deals are relatively common for celebrities. In posts to Instagram and Facebook earlier this month Kardashian talks about her struggles with nausea due to pregnancy.
“I tried changing things about my lifestyle, like my diet, but nothing helped, so I talked to my doctor,” the post states. “He prescribed me #Diclegis, and I felt a lot better and most importantly, it’s been studied and there was no increased risk to the baby.”
But FDA regulators say the posts violate rules for promoting drugs because they don’t mention side effects of Diclegis, which include sleepiness that can make it dangerous to drive or perform other activities that require mental alertness.
FDA regulators are “concerned that Duchesnay is continuing to promote Diclegis in a violative manner,” states the letter dated Aug. 7.
The FDA approved Dicleglis in 2013 to treat vomiting and nausea in pregnant women who do not respond to more traditional measures. It is the only prescription drug approved in the U.S. for morning sickness.
Kardashian’s publicist did not immediately respond to a request for comment Tuesday.
Kim K John Paul Filo/AP Kourtney, left, and Kim Kardashian talk with host David Letterman on the set of the “Late Show with David Letterman,” ...
LOS ANGELES—Kim Kardashian West says she “mentally prepped” herself to be raped while being held at gunpoint during a Paris jewelry heist last year.Kardashian West ...
Mifegymiso was approved for sale in Canada in July 2015, but it has only become available this month. (Charlie Neibergall/Associated Press) A year and a ...